Insperity heads into its third-quarter report with a turnaround story that has already been told and partly priced. The profit rebuild that began after last year's healthcare-cost collapse has gone well, and management raised its full-year outlook in July. Shares have still fallen 10% since that report, while the S&P 500 rose 4.5%. That gap leaves the October 29 premarket release with one job: show that the margin repair can hold through the quarter management itself flagged as the riskiest of the year.
Wall Street expects adjusted earnings of $0.20 per share on revenue of $1.63 billion. Revenue growth of 0.4% would leave the top line essentially flat. That matters because a professional employer organization like Insperity grows mainly by adding worksite employees, and management still expects that count to shrink by 1% to 1.6% this year. The comparison is easy on earnings. A year ago the company posted an adjusted loss of $0.20 per share, the start of its healthcare-cost crisis, so almost any profit counts as recovery. The real test is against guidance.
Management guided third-quarter adjusted EPS between a loss of $0.09 and a profit of $0.41. That is an unusually wide band with a midpoint near $0.16. Consensus sits modestly above that midpoint, and the $0.25 whisper number is higher still. So the informal bar asks the company to land in the upper half of its own range. For the full year, guidance runs from $1.88 to $2.43, and the $2.07 consensus sits below the midpoint. The Street is betting on a decent third quarter but remains wary that the fourth quarter could disappoint.
That caution traces back to the July call. The finance chief deliberately set a second-half EBITDA range of about $40 million, compared with the $25 million to $30 million he normally uses. He cited stubbornly elevated healthcare cost trends. This quarter will show whether that cushion was prudence or foresight. The recovery plan has three legs:
1. Repricing and better client mix.
2. A reworked UnitedHealthcare contract and plan design changes.
3. Tight expense control, with operating expenses down 8% in the second quarter.
The cleanest scorecard is gross profit per worksite employee. It fell 21% in the fourth quarter of 2025, then narrowed to a 1% decline at $237 a month in the second quarter. Holding near flat or turning positive would confirm the pricing actions are sticking. Slipping back would suggest claims costs are again outrunning pricing. Workers' compensation is a smaller swing factor. Favorable reserve releases from prior years faded last quarter as claims severity rose across the industry.
The growth story needs evidence too. HR Scale, the offering aimed at larger clients, entered the quarter with about 8,000 sold worksite employees and more than 5,000 already live. That was ahead of the 6,000 to 8,000 year-end target set in February. Steady conversion of the roughly 3,000 still in implementation would support the 2027 growth case. Two other signals matter as fall selling season gets underway. Management said sales and client retention were finishing at the low end of historical ranges, so any improvement there would help. So would wider adoption of insurance options sold through the company's agency, which now cover 14% of new clients and reduce Insperity's exposure to its own benefit plan.
Sentiment has edged from moderately bearish before the last report to roughly neutral. The stock trades at $50.02, well above its 200-day average of $39.21. It sits mid-range between its post-earnings low of $45.66 and high of $55.60, after a huge run from below $28 in the prior quarter. That positioning suggests investors have banked the recovery and paused, waiting for proof. The report will keep the narrative intact if healthcare costs stay contained enough for profit per worksite employee to hold steady. If they do not, the wider guidance range will look less like caution and more like a warning.